β-defensin 27 Inhibitors
β-defensin 27 inhibitors are a class of chemical agents that target and modulate the function of β-defensin 27, a member of the defensin family of peptides. Defensins are small, cysteine-rich cationic proteins that play crucial roles in biological processes such as host-microbe interactions, cellular signaling, and innate immune responses. β-defensin 27, in particular, is a peptide that can be involved in modulating cell signaling pathways and mediating interactions between cells and their environments. The inhibitors designed to specifically interact with β-defensin 27 aim to bind to its active or regulatory sites, altering its ability to participate in biological functions such as peptide aggregation or receptor interaction. These inhibitors can function by preventing β-defensin 27 from binding to its target ligands, disrupting the peptide's structural conformation, or by directly inhibiting the synthesis of the peptide itself through biochemical interference with its genetic expression pathways.
Structurally, β-defensin 27 inhibitors may exhibit diverse molecular characteristics, ranging from small organic molecules to larger peptides or proteins. The design of these inhibitors often leverages detailed knowledge of the peptide's secondary and tertiary structure, specifically focusing on regions essential for β-defensin 27's biological activities. Some inhibitors are designed to mimic the peptide's natural substrates, competing with them for binding and thereby reducing the peptide's functional availability. Others may act as allosteric inhibitors, binding to alternative sites on the peptide and inducing conformational changes that reduce its activity. The study of β-defensin 27 inhibitors provides important insights into the broader mechanistic roles of defensins, contributing to the understanding of how these peptides modulate cellular homeostasis, membrane permeability, and protein-protein interactions within various cellular environments.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that disrupts the degradation of proteins. Bortezomib indirectly suppresses β-defensin 27 by interfering with NF-κB activation, a key regulator of β-defensin 27 transcription. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
An irreversible PI3K inhibitor disrupting the PI3K/AKT pathway. Wortmannin indirectly inhibits β-defensin 27 expression by blocking AKT, a downstream effector involved in the regulation of β-defensin 27 transcription. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
An NFAT inhibitor that disrupts the calcineurin pathway. Cyclosporin A indirectly suppresses β-defensin 27 by inhibiting NFAT activation, which is involved in the transcriptional regulation of β-defensin 27. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor influencing the AP-1 pathway. SB203580 indirectly hinders β-defensin 27, as the AP-1 transcription factor, downstream of p38 MAPK, is involved in the transcriptional regulation of β-defensin 27. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
An HDAC inhibitor affecting chromatin remodeling. Vorinostat indirectly suppresses β-defensin 27 by modulating histone acetylation, influencing the accessibility of the β-defensin 27 gene for transcription. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
A Wnt/β-catenin pathway inhibitor. XAV939 indirectly inhibits β-defensin 27, as the Wnt/β-catenin pathway has been implicated in regulating β-defensin 27 expression through modulation of specific transcription factors. | ||||||
Quinomycin A | 512-64-1 | sc-202306 | 1 mg | $166.00 | 4 | |
A HIF-1α inhibitor affecting the hypoxia pathway. Echinomycin indirectly suppresses β-defensin 27 by blocking HIF-1α, which normally enhances β-defensin 27 transcription under hypoxic conditions. | ||||||
Resatorvid | 243984-11-4 | sc-476758 | 5 mg | $367.00 | ||
A TLR4 antagonist inhibiting the TLR4 signaling pathway. TAK-242 indirectly hampers β-defensin 27, as TLR4 activation is known to upregulate β-defensin 27 expression through NF-κB and AP-1 signaling cascades. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor influencing the mTORC1 pathway. Rapamycin indirectly inhibits β-defensin 27 by modulating mTORC1 signaling, which is implicated in the regulation of β-defensin 27 through translation initiation control. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
A Notch signaling pathway inhibitor. DAPT indirectly suppresses β-defensin 27, as Notch signaling is linked to the regulation of β-defensin 27 expression by modulating specific transcription factors. | ||||||